Evaxion Biotech Files 6-K, Incorporates by Reference

Ticker: EVAX · Form: 6-K · Filed: 2025-02-12T00:00:00.000Z

Sentiment: neutral

Topics: reporting, foreign-private-issuer, registration-statement

Related Tickers: EVX

TL;DR

EVX files 6-K, incorporating into existing filings. Standard reporting.

AI Summary

Evaxion Biotech A/S filed a Form 6-K on February 12, 2025, for the month of February 2025. This report is incorporated by reference into several of their existing registration statements on Forms S-8 and F-3, as well as multiple F-1 filings. The company is a foreign private issuer based in Hoersholm, Denmark.

Why It Matters

This filing indicates ongoing reporting and compliance activities for Evaxion Biotech, potentially affecting investor confidence and the availability of securities under existing registration statements.

Risk Assessment

Risk Level: low — This is a routine filing for a foreign private issuer, primarily incorporating previous information into existing registration statements, and does not appear to contain new material financial or operational disclosures.

Key Numbers

Key Players & Entities

FAQ

What is the purpose of this Form 6-K filing?

This Form 6-K is a report of a foreign private issuer for the month of February 2025, and it is being incorporated by reference into Evaxion Biotech A/S's existing registration statements.

Which registration statements is this 6-K filing being incorporated into?

This filing is incorporated by reference into Evaxion Biotech A/S's registration statements on Form S-8 (File No. 333-255064), Form F-3 (File No. 333-265132), and multiple Form F-1 filings (File Nos. 333-266050, 333-276505, 333-279153, and 333-283304).

What is Evaxion Biotech A/S's principal executive office address?

The principal executive offices are located at Dr. Neergaards Vej 5f, DK-2970 Hoersholm, Denmark.

Is Evaxion Biotech A/S required to file annual reports under Form 20-F or Form 40-F?

Yes, Evaxion Biotech A/S indicates it files annual reports under cover of Form 20-F.

When was this Form 6-K filed?

This Form 6-K was filed on February 12, 2025.

From the Filing

0001171843-25-000757.txt : 20250212 0001171843-25-000757.hdr.sgml : 20250212 20250212080059 ACCESSION NUMBER: 0001171843-25-000757 CONFORMED SUBMISSION TYPE: 6-K PUBLIC DOCUMENT COUNT: 3 CONFORMED PERIOD OF REPORT: 20250212 FILED AS OF DATE: 20250212 DATE AS OF CHANGE: 20250212 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Evaxion Biotech A/S CENTRAL INDEX KEY: 0001828253 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 000000000 STATE OF INCORPORATION: G7 FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 6-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-39950 FILM NUMBER: 25612059 BUSINESS ADDRESS: STREET 1: DR NEERGAARDS VEJ 5F CITY: HOERSHOLM STATE: G7 ZIP: 2970 BUSINESS PHONE: 4552656554 MAIL ADDRESS: STREET 1: DR NEERGAARDS VEJ 5F CITY: HOERSHOLM STATE: G7 ZIP: 2970 6-K 1 f6k_021125.htm FORM 6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO SECTION 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of February 2025 Commission File Number: 001-39950 Evaxion Biotech A/S (Exact Name of Registrant as Specified in Its Charter) Dr. Neergaards Vej 5f DK-2970 Hoersholm Denmark (Address of principal executive offices) Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F. Form 20-F ☒ Form 40-F ☐ INCORPORATION BY REFERENCE This report on Form 6-K shall be deemed to be incorporated by reference in Evaxion Biotech A/S’s registration statements on Form S-8 (File No. 333-255064), on Form F-3 (File No. 333-265132), on Form F-1, as amended (File No. 333-266050), Form F-1 (File No. 333-276505), Form F-1 (File No. 333-279153), and Form F-1 (File No. 333-283304), including any prospectuses forming a part of such registration statements and to be a part thereof from the date on which this report is filed, to the extent not superseded by documents or reports subsequently filed or furnished. Amendment to Articles of Association Capital Increases As previously announced on January 31, 2025, Evaxion Biotech A/S (the “Company”) recently closed its public offering of an aggregate of 3,997,361 of its American Depositary Shares (“ADSs”) and warrants to purchase up to 50% of the ADSs offered at a combined public offering price of $2.71 per ADS with one accompanying warrant for each two ADSs. In connection with the closing of its public offering, the Company registered aggregate share capital increases of nominal DKK 49,967,012.50 with the Danish Business Authority, with effective date of January 31, 2025, corresponding to an aggregate increase in the Company’s share capital to nominal DKK 78,332,151.50. This reflected issuances of 199,868,050 shares in connection with the public offering. The Articles of Association were also amended to provide for the granting of up to 1,998,675 warrants to purchase up to 1,998,675 ADSs representing 99,933,750 ordinary shares, with the terms set forth in detail in appendix 11 of the Articles of Association. The warrants set forth in Appendix 11 have a term of 5 years and an exercise price of $2.71. Following the public offering the authorization in article 2.11 of the Articles of Association to grant warrants to investors, lenders, consultants and/or advisors in the company is reduced to warrants entitling the holders thereof to subscribe for shares up to a nominal value of DKK 59,921,500. The Articles of Association were also amended in connection with the exercise of certain investor warrants. The Company registered share capital increases in aggregate nominal DKK 625,000 ordinary shares with the Danish Business Authority, with effective date of February 5, 2025, corresponding to an aggregate increase in the Company’s share capital to nominal DKK 78,957,151.50, in connection with the exercise of such warrants on February

View on Read The Filing